Clinical Trials Browser

Phase 2 × Completed × umbralisib × Clear all

NCT04508647 2024-03-21

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Phase 2 Completed

4 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03364231 2023-06-23

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

21 enrolled 14 charts

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone